Bal Pharma Ltd
NSE:BALPHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lockheed Martin Corp
NYSE:LMT
|
US |
ROCE
Return on Capital Employed (ROCE) measures how efficiently a company uses its capital to generate profit. It shows how much net income is earned for each dollar of capital employed.
Return on Capital Employed (ROCE) measures how efficiently a company uses its capital to generate profit. It shows how much net income is earned for each dollar of capital employed.
Peer Comparison
| Country | Company | Market Cap | ROCE | ||
|---|---|---|---|---|---|
| IN |
B
|
Bal Pharma Ltd
NSE:BALPHARMA
|
1.2B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD |
Loading...
|
Market Distribution
| Min | -2 275.6% |
| 30th Percentile | 2.6% |
| Median | 8.7% |
| 70th Percentile | 15.3% |
| Max | 5 652.3% |
Other Profitability Ratios
Bal Pharma Ltd
Glance View
Bal Pharma Ltd. is a holding company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The firm is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). The firm specializes in prescription drugs, generic, over the counter (OTC) products, intravenous infusion and bulk actives. The company offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, and diuretic, acne treatment. The company also manufactures and supplies natural medicines in the segment of bulk actives, formulations, generics and herbals. Its finished formulation products covers dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, Ophthalmic, creams and ointments. The firm offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.
See Also
ROCE is calculated by dividing the EBIT by the Avg Capital Employed.
The current ROCE for Bal Pharma Ltd is 15.7%, which is below its 3-year median of 16.3%.
Over the last 3 years, Bal Pharma Ltd’s ROCE has increased from 11.5% to 15.7%. During this period, it reached a low of 11% on Jun 30, 2023 and a high of 19.8% on Dec 31, 2024.
